Fernando Henao

Hospital Universitario Virgen Macarena

Author Statistics

Papers

Citation

H-Index

i-10 index

Research Trends

Author Order

Document Type

Co-Authors

Luís de la Cruz-Merino

Hospital Universitario Virgen Macarena

Serafín Morales

Complejo Asistencial Sótero del Río

Pablo Tolosa

Research Institute Hospital 12 de Octubre

Natalia Palazón‐Carrión

Hospital Universitario Virgen Macarena

Vanesa Quiroga

Institut Català d'Oncologia

Vı́ctor Sánchez-Margalet

Universidad de Sevilla

Francisco Ayala de la Peña

Hospital General Universitario Morales Meseguer

E. González

Hospital Universitario Virgen de las Nieves

Raquel Andrés

Hospital Clínico Universitario Lozano Blesa

Esteban Nogales Fernández

Hospital Universitario Virgen Macarena

Cooperative Institutions

GEICAM – Spanish Breast Cancer Group

Hospital Universitario Virgen Macarena

Dana-Farber Cancer Institute

Centro de Investigación Biomédica en Red de Cáncer

Institut Català d'Oncologia

International Breast Cancer Study Group

Roche (Switzerland)

Solti

Memorial Sloan Kettering Cancer Center

Ludwig-Maximilians-Universität München

Author Statistics

Papers

Citation

H-Index

i-10 index

Research Field

LBA3 SOLTI-1507 IPATHER: Primary results of the phase Ib study of ipatasertib (IPAT) and dual anti-HER2 therapy with trastuzumab and pertuzumab (HP) in patients (pts) with PIK3CA mutant (mut) HER2+ advanced breast cancer (ABC)

ESMO Open (2024)

M. Oliveira Eva Ciruelos Serafín Morales F.J. Salvador Bofill Vanesa Garcı́a

In the CLEOPATRA trial, pts with HER2+ PIK3CAmut ABC had a shorter progression-free survival (PFS) than those with PIK3CAwt. We hypothesized that IPAT, an AKT inhibitor with activity in PI3K/AKT-altered tumors, combined with HP was both safe and effective in PIK3CAmut HER2+ ABC. IPATHER is an open-label, single-arm, phase Ib trial that evaluates the safety and efficacy of IPAT + HP in pts with PIK3CAmut HER2+ ABC candidates to maintenance HP following discontinuation of first-line chemotherapy (CT) for reasons other than progressive disease. The primary aim was to determine the maximum tolerated dose (MTD) of IPAT + HP, defined as the highest dose at which ≤1 of the first 6 pts enrolled experienced a dose-limiting toxicity (DLT: grade [G] ≥3 diarrhea >72 hours, G ≥2 diarrhea >5 days [d], other treatment related adverse events [TRAEs] G ≥ 3) during the first 28d of treatment. Initial IPAT dose was 400mg d1-21 in 28d cycles with standard dose HP (de-escalation doses are 300mg and 200mg). Secondary aims included safety, overall response rate (ORR), clinical benefit rate (CBR), and PFS. PIK3CAmut was detected in 24/108 HER2+ tumors (22%). From Feb/2020 to Nov/2023, 17 pts were enrolled, median age 54 (41-78). Most had HR- tumors, visceral metastases, and stage IV disease at diagnosis (59% each). At data cut-off (April 2024), 6 pts (35%) remained on treatment. No DLTs were observed in the first 6 pts and IPAT 400mg + HP was defined as MTD. In the remaining 11 pts, 3 had a DLT (G3 diarrhea, G3 vomiting, and G3 rash). The most common TRAEs were diarrhea (82%), nausea (47%), decreased appetite (35%), and fatigue, rash, and vomiting (29% each). G3/4 TRAEs occurred in 35%; most common were diarrhea and nausea (12% each). With a median follow-up of 19.9 months (m), confirmed ORR was 31%, CBR 69%, and median PFS 15.4m (9.4-NR), with 48% pts progression-free after 18m from enrollment. Maintenance treatment with IPAT 400mg + HP following CT had an acceptable safety profile and showed promising efficacy in pts with PIK3CAmut HER2+ ABC. Combining a PI3K/AKT pathway inhibitor with anti-HER2 treatment in this setting merits further evaluation.

Pertuzumab

10.1016/j.esmoop.2024.103480

Cite

Citations (0)

Linfangitis carcinomatosa como presentación de un adenocarcinoma gástrico

Revista Andaluza de Patología Digestiva (2010)

Fernando Henao L. Grueso López Luís de la Cruz-Merino

Source

Cite

Citations (0)

Real-world experience with pertuzumab and trastuzumab combined with chemotherapy in neoadjuvant treatment for patients with early-stage HER2-positive breast cancer: the NEOPERSUR study

Clinical & Translational Oncology (2024)

Alejandro Falcón Josefina Cruz Jurado E. Llabrés Valentí Rocío Urbano Cubero Maria Carmen Álamo de la Gala

HER2-targeted therapies have dramatically improved outcomes of patients with HER2-positive breast cancer (BC), as demonstrated in neoadjuvant trials. This study aims to provide real-world evidence on the use and effectiveness of combined pertuzumab, trastuzumab and chemotherapy (CT) in early-stage HER2-positive BC.

Pertuzumab

Taxane

Lapatinib

Neoadjuvant Therapy

Carboplatin

Breast-conserving surgery

Clinical endpoint

10.1007/s12094-024-03440-5

Cite

Citations (1)

Supportive Care in Cancer (2015)

R. de las Peñas Santiago Ponce Fernando Henao Carlos Camps Enric Carcereny

Hyponatremia (Na ˂135 mmol/l) is the most frequent electrolyte disorder in clinical practice, and the syndrome of inappropriate antidiuretic hormone secretion (SIADH) is the commonest cause of hyponatremia in cancer patients. Correcting hyponatremia in these patients can reduce morbidity and mortality, increase the response to anti-cancer agents, and help reduce hospital length of stay and costs. Tolvaptan is an oral medication used to treat SIADH-related hyponatremia patients that needs to be initiated at hospital so patients can have their serum sodium monitored. If tolvaptan could be initiated in hospital day care units (DCUs), performing the same tests, hospitalization could be avoided, quality of life improved, and costs reduced. This is the first publication where a panel of oncologists are sharing their experience and making some recommendations with the use of tolvaptan to treat SIADH-related hyponatremia in DCU after collecting and examining 35 clinical cases with these type of patients. The conclusion from this retrospective observational analysis is that the use of tolvaptan in DCU is safe and effective in the therapeutic management of SIADH-related hyponatremia.

Tolvaptan

Electrolyte Disorder

10.1007/s00520-015-2948-6

Cite

Citations (12)

SEOM clinical guidelines for the prophylaxis of infectious diseases in cancer patients (2021)

Clinical & Translational Oncology (2022)

Isabel Echavarría Jorge Galindo J. Corral María Pilar Diz Taín Fernando Henao

Infections are still a major cause of morbi-mortality in patients with cancer. Some of these infections are preventable through specific measures, such as vaccination or prophylaxis. This guideline aims to summarize the evidence and recommendations for the prevention of infections in cancer patients, devoting special attention to the most prevalent preventable infectious disease. All the evidences will be graded according to The Infectious Diseases Society of America grading system.

Guideline

Grading (engineering)

10.1007/s12094-022-02800-3

Cite

Citations (6)

351TiP SOLTI-1507: A phase Ib study of ipatasertib and anti-HER2 therapy in HER2-positive advanced breast cancer with PIK3CA mutation (IPATHER)

Annals of Oncology (2020)

Mafalda Oliveira Patricia Villagrasa Eva Ciruelos Joaquín Gavilá Alexandra Cortegoso

Pertuzumab

Taxane

Neratinib

Clinical endpoint

10.1016/j.annonc.2020.08.453

Cite

Citations (1)

Correction: SEOM-GEICAM-SOLTI clinical guidelines for early-stage breast cancer (2022)

Clinical & Translational Oncology (2023)

Francisco Ayala de la Peña Silvia Antolín Joaquín Gavilá Gregori Lucía González Cortijo Fernando Henao

10.1007/s12094-023-03334-y

Cite

Citations (0)

234P Real-world treatment patterns and outcomes of patients receiving palbociclib plus endocrine therapy in Spain: Subgroup analysis based on age, sites and number of metastatic locations, menopausal status and dose received from PALBOSPAIN study

ESMO Open (2023)

Fernando Moreno Antón M. Bellet-Ezquerra L.M. Manso Sànchez Fernando Henao Antonio Antón Torres

PALBOSPAIN is an observational, multicenter study to evaluate real-world practice patterns and outcomes of first-line treatment for advanced breast cancer (ABC) with Palbociclib. Results from real-world progression free survival (rwPFS) and overall survival (OS) in the total population and according to endocrine sensitivity have been previously reported. Here, we provide subgroup analysis according to age, sites and number of metastatic locations, menopausal status, and dose received. Patients diagnosed with HR+/HER2- ABC who had started first-line treatment with palbociclib between November 2017 and November 2019 were included. 762 patients received Palbociclib in combination with AIs (69.4%) or fulvestrant (30.1%). Median age was 61.9 years (17.5% < 50 y; 51.8% 50-70 y; 30.7% > 70 y). 114 patients were premenopausal (15%). A total of 418 patients had visceral disease (54.9%). At baseline, patients with 1, 2-3 and >3 metastatic locations were 42.7%, 43% and 14.3% respectively. Results of real-world Response Rate (rwRR) and rwPFS are shown in the table. A total of 377 (49.5%) patients required a dose reduction. Among patients who had a first dose reduction, 164 (21.5%) required a second dose reduction. Median rwPFS was 28 months (CI 95% 25-33) in patients who had ≥ 1 dose reductions and 19 months (CI 95% 16-23) in patients who maintained the initial dose (HR 0.71; CI 95% 0.58-0.85, p=0.003). Table: 234PrwRRrwPFSCRPRSDPDN (%)N (%)N ( %)N ( %)Months CI 95%Age<5015 (11.3)50 (37.6)46 (34.6)19 (14.3)27 (21-35)50-7022 (5.6)145 (36.7)152 (38.5)57 (14.4)21 (19-26)>7013 (5.6)87 (37.2)88 (37.6)31 (13.2)27 (22-37)Menopausal statusPremenopausal13 (11.4)44 (38.6)40 (35.1)15 (13.2)27 (20-35)Postmenopausal37 (5.7)238 (36.3)246 (38)92 (14.2)24 (21-27)Visceral metastasisYes21 (7.4)17 (41.4)141 (33.7)63 (15.1)20 (18-23)No29 (8.4)109 (31.7)145 (42.2)44 (12.8)30 (25-36)Nº of locations124 (7.4)100 (30.8)136 (41.8)46 (14.2)34 (28-39)2-323 (7.0)132 (40.2)116 (35.4)47 (14.3)20 (18.24)>33 (2.8)50 (45.9)34 (31.2)14 (12.8)19 (14-24)CR, complete response; PR, partial response; SD, stable disease; PD, progressive disease; NA, not available; NR, not reached Open table in a new tab CR, complete response; PR, partial response; SD, stable disease; PD, progressive disease; NA, not available; NR, not reached Age at start of the treatment and menopausal status were not associated with PFS. Patients with visceral metastasis and >1 sites of metastasis had shorter PFS. The incidence of dose reductions was higher compared with PALOMA-2 & 3 trials. However, dose reductions did not affect Palbociclib efficacy.

Palbociclib

Fulvestrant

Subgroup analysis

10.1016/j.esmoop.2023.101422

Cite

Citations (2)

Myeloid derived-suppressor cells in healthy women and in advanced breast cancer patients

Annals of Oncology (2019)

Natalia Palazón‐Carrión M.L. Sánchez León C. Jiménez Cortegana Francisco José Valdivia García I. Araujo Fernández

Background: In advanced breast cancer (ABC) some studies suggest a deleterious effect on survival when high levels of myeloid-derived suppressor cells (MDSC)1,2 are detected in peripheral blood. Furthermore, classical therapies like anthracyclines or gemcitabine seem to exert an immunostimulating effect by eliminating and/or altering the function of MDSC3. The objective of this study is to analyze the evolution of blood MDSC in patients with ABC prior to the standard first-line systemic therapy according to Clinical Practice Guidelines. Methods: MDSC levels are measured at three timepoints: basal, and after 2 and 6 months from first line systemic therapy onset. Data are compared the measurements obtained from the MDSC of a control group of healthy women. In addition, MDSC levels are monitorized and correlated with clinical outcomes in terms of overall response rate [clinical benefit (CB, complete response + partial response + stabilization lasting more than 24 weeks) versus (vs.) progression of disease (PD)]. Results: A total of 39 patients with ABC (34 CB, 5 PD) and 20 healthy women have been analyzed. 34 out of 39 patients were considered to obtain CB and 5 patients (12,82%) had PD as best response. Basal MDSC levels were higher in ABC patients prior to initiate any systemic therapy vs healthy population (p < 0,001). The levels of MDSC decreased sharply in those patients with CB (p 0,001), reaching statistical significance. However, no statistically significant differences were found in patients with PD (p 0,317) with respect to basal levels of MDSC (Table). Conclusions: Basal MDSC levels are higher in patients diagnosed with ABC compared to the healthy population. Systemic therapy seems to decrease the levels of blood MDSC of patients with ABC, which may eventually help to restore a better immunosurveillance profile in ABC patients that could impact on clinical evolution. Legal entity responsible for the study: The authors. Funding: Andalusian Public Progress and Health Foundation. Disclosure: All authors have declared no conflicts of interest. Table59P Evolution of the MDSC according to clinical response in ABC and basal MDSC in healthy cohortMDSC_Basal (mean)MDSC_Cycle_3 (mean)MDSC_Cycle_6 (mean)P valuePD ABC25,97 (95% CI: 6,47-45,47)5,38 (95% IC: 4,05-6,71)1,79*There is only one patient analyzed in cycle 6 with PD. DP, progression of disease; CB, clinical benefit; ABC, advanced breast carcinoma; MDSC, myeloid-derived suppressor cells; 95% CI, 95% confidence interval.0,317CB ABC13,03 (95% CI: 7,24-18,83)3,90 (95% IC: 2,56-5,23)2,98 (95% IC: 1,99-3,98)0,001Healthy cohort0,81 (95% CI: 0,52-1,10)––<0,001* There is only one patient analyzed in cycle 6 with PD. DP, progression of disease; CB, clinical benefit; ABC, advanced breast carcinoma; MDSC, myeloid-derived suppressor cells; 95% CI, 95% confidence interval. Open table in a new tab

Basal (medicine)

10.1093/annonc/mdz095.058

Cite

Citations (1)

Triple negative breast cancer: second and successive lines of treatment

Revisiones en Cáncer (2023)

Fernando Henao Sara Leal Sánchez

Triple-negative breast cancer

10.20960/revcancer.00033

Cite

Citations (0)